Friday, September 14, 2012

Pfizer settles litigation with Mylan on Detrol LA (tolterodine tartrate)


 
Pfizer Inc. has settled its litigation against Mylan Inc., a generic pharmaceutical manufacturer, and Mylan Pharmaceuticals Inc. relating to Pfizer's patents covering Detrol LA, or tolterodine tartrate, extended-release capsules.
As a result of this settlement, and past settlements related to these patents, Pfizer expects generic competition for Detrol LA to commence in the US no earlier than January 1, 2014, except in certain limited circumstances, and no later than March 1, 2014.